Verve Therapeutics (VERV) News Today $5.16 -0.03 (-0.48%) Closing price 03:59 PM EasternExtended Trading$5.14 -0.02 (-0.39%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period PDT Partners LLC Sells 128,512 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)PDT Partners LLC lessened its position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 70.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 53,291 shares of the company's stock after selMay 5 at 5:11 AM | marketbeat.comSusquehanna Fundamental Investments LLC Invests $1.64 Million in Verve Therapeutics, Inc. (NASDAQ:VERV)Susquehanna Fundamental Investments LLC acquired a new stake in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 291,383 shares of the company's stock,May 3 at 5:08 AM | marketbeat.comVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 2 at 4:05 PM | globenewswire.comSchonfeld Strategic Advisors LLC Boosts Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)Schonfeld Strategic Advisors LLC increased its holdings in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 57.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,789,379 shares of the comMay 2 at 6:32 AM | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Shares Sold by T. Rowe Price Investment Management Inc.T. Rowe Price Investment Management Inc. trimmed its holdings in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 3.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,352,599 shares of the compaApril 30, 2025 | marketbeat.com1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall StreetApril 29, 2025 | fool.comSyon Capital LLC Takes $302,000 Position in Verve Therapeutics, Inc. (NASDAQ:VERV)Syon Capital LLC purchased a new position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 53,469 shares of the company's stApril 28, 2025 | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Shares Sold by Renaissance Technologies LLCRenaissance Technologies LLC lessened its position in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 36.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 363,400 shares of the company's stApril 28, 2025 | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Position Reduced by JPMorgan Chase & Co.JPMorgan Chase & Co. lowered its stake in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 74.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 417,539 shares of the company's stock after selling 1,230,305 shares during the period. JPMorgan Chase & Co. oApril 26, 2025 | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Given Average Recommendation of "Buy" by AnalystsVerve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) has been assigned an average rating of "Buy" from the six ratings firms that are currently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12 month target price amoApril 21, 2025 | marketbeat.comWhy Verve Therapeutics Zoomed 40% Higher This WeekApril 18, 2025 | fool.comVerve Therapeutics Sees Unusually Large Options Volume (NASDAQ:VERV)Verve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) was the target of some unusual options trading on Tuesday. Traders acquired 7,528 call options on the company. This is an increase of approximately 2,795% compared to the average daily volume of 260 call options.April 17, 2025 | marketbeat.comGuggenheim Raises Verve Therapeutics (NASDAQ:VERV) Price Target to $24.00Guggenheim boosted their target price on shares of Verve Therapeutics from $18.00 to $24.00 and gave the company a "buy" rating in a report on Tuesday.April 17, 2025 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Upgraded to Overweight at Cantor FitzgeraldCantor Fitzgerald upgraded Verve Therapeutics from a "neutral" rating to an "overweight" rating in a report on Tuesday.April 17, 2025 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Stock Price Expected to Rise, Canaccord Genuity Group Analyst SaysCanaccord Genuity Group upped their price target on Verve Therapeutics from $32.00 to $39.00 and gave the stock a "buy" rating in a report on Tuesday.April 17, 2025 | marketbeat.comBiotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More NewsApril 17, 2025 | finance.yahoo.comHC Wainwright Forecasts Strong Price Appreciation for Verve Therapeutics (NASDAQ:VERV) StockHC Wainwright upped their price target on Verve Therapeutics from $15.00 to $25.00 and gave the stock a "buy" rating in a report on Monday.April 16, 2025 | marketbeat.comJ.P. Morgan Sticks to Their Hold Rating for Verve Therapeutics (VERV)April 16, 2025 | markets.businessinsider.comVerve extends gains as Cantor Fitzgerald upgrades on data for cholesterol drugApril 15, 2025 | msn.comVerve Therapeutics price target raised to $24 from $18 at GuggenheimApril 15, 2025 | markets.businessinsider.comCantor upgrades Verve Therapeutics to Overweight after positive dataApril 15, 2025 | markets.businessinsider.comWhy Verve Therapeutics Is Skyrocketing TodayApril 15, 2025 | fool.comVerve Therapeutics price target raised to $25 from $15 at H.C. WainwrightApril 15, 2025 | markets.businessinsider.comVerve jumps after early-stage trial data for gene editing therapyApril 14, 2025 | msn.comVerve’s second swing at gene editing for heart disease shows early promiseApril 14, 2025 | finance.yahoo.com6VERV : Assessing Verve Therapeutics:...April 14, 2025 | benzinga.comVerve’s shares jump by more than 26% on Lilly-partnered gene therapy dataApril 14, 2025 | finance.yahoo.comThis Cholesterol Gene Medicine Could Work in 1 Shot. It Could Also Bring This Biotech Stock Back to Life.April 14, 2025 | msn.comVerve Therapeutics Touts Positive Data From Gene Editing Medicine To Lower Cholesterol After Single DoseApril 14, 2025 | benzinga.comVerve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9April 14, 2025 | globenewswire.comNorges Bank Purchases Shares of 78,186 Verve Therapeutics, Inc. (NASDAQ:VERV)Norges Bank acquired a new position in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 78,186 shares of the company's stock, valued at approximatApril 14, 2025 | marketbeat.comVerve Therapeutics receives FDA Fast Track designation for VERVE-102April 11, 2025 | markets.businessinsider.comVerve Therapeutics Gets FDA Fast-Track Designation for Verve-102April 11, 2025 | marketwatch.comVerve Therapeutics wins FDA fast track status for cholesterol treatmentApril 11, 2025 | msn.comVerve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9April 11, 2025 | globenewswire.comVerve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Trexquant Investment LPTrexquant Investment LP raised its position in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 14.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 635,847 shares of the company's stock after purchasing an additiApril 8, 2025 | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Insider Joan Nickerson Sells 2,777 SharesVerve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) insider Joan Nickerson sold 2,777 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $4.15, for a total transaction of $11,524.55. Following the transaction, the insider now owns 17,420 shares in the company, valued at $72,293. The trade was a 13.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.April 5, 2025 | marketbeat.comAllison Dorval Sells 3,350 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) StockVerve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) CFO Allison Dorval sold 3,350 shares of the stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $4.15, for a total transaction of $13,902.50. Following the completion of the transaction, the chief financial officer now directly owns 13,280 shares of the company's stock, valued at approximately $55,112. The trade was a 20.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.April 5, 2025 | marketbeat.comVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 4, 2025 | globenewswire.comVerve Therapeutics, Inc. (NASDAQ:VERV) Insider Sells $11,524.55 in StockApril 4, 2025 | insidertrades.comIs Verve Therapeutics, Inc. (VERV) the Best Gene-Editing Stock to Buy?April 2, 2025 | finance.yahoo.com8 Best Gene-Editing Stocks to BuyApril 2, 2025 | insidermonkey.comIs Verve Therapeutics, Inc. (VERV) the Best Gene-Editing Stock to Buy?April 1, 2025 | insidermonkey.comWilliam Blair Sticks to Its Buy Rating for CAMP4 Therapeutics Corporation (CAMP)March 28, 2025 | markets.businessinsider.comVerve Therapeutics, Inc. (NASDAQ:VERV) Given Consensus Recommendation of "Buy" by AnalystsShares of Verve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) have earned an average rating of "Buy" from the six research firms that are presently covering the stock, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year price taMarch 26, 2025 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Given "Buy" Rating at GuggenheimGuggenheim reiterated a "buy" rating on shares of Verve Therapeutics in a research note on Tuesday.March 26, 2025 | marketbeat.comVerve Therapeutics' (VERV) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $15.00 price target on shares of Verve Therapeutics in a report on Tuesday.March 26, 2025 | marketbeat.comVerve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 CatalystsMarch 25, 2025 | seekingalpha.comWilliam Blair Remains a Buy on Verve Therapeutics (VERV)March 25, 2025 | markets.businessinsider.comVerve Therapeutics announces FDA clearance of IND application for VERVE-102March 24, 2025 | markets.businessinsider.com Get Verve Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter. Email Address VERV Media Mentions By Week VERV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VERV News Sentiment▼1.140.72▲Average Medical News Sentiment VERV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VERV Articles This Week▼66▲VERV Articles Average Week Get Verve Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Bausch Health Companies News Today Beam Therapeutics News Today NewAmsterdam Pharma News Today Vericel News Today Belite Bio News Today Tarsus Pharmaceuticals News Today Janux Therapeutics News Today Schrödinger News Today Arrowhead Pharmaceuticals News Today Centessa Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VERV) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verve Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VERV Stock Free VERV Stock Alerts